Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Rating) – Equities researchers at Cantor Fitzgerald dropped their FY2022 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a report released on Monday, June 20th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings per share of ($0.63) for the year, down from their prior forecast of ($0.57). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.31) per share. Cantor Fitzgerald also issued estimates for Cardiol Therapeutics’ FY2023 earnings at ($0.24) EPS.
Separately, Canaccord Genuity Group reduced their target price on Cardiol Therapeutics from $8.00 to $7.00 in a research note on Tuesday, April 19th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brookstone Capital Management purchased a new position in shares of Cardiol Therapeutics during the 4th quarter valued at about $27,000. Private Ocean LLC raised its stake in shares of Cardiol Therapeutics by 275.5% during the 4th quarter. Private Ocean LLC now owns 20,651 shares of the company’s stock valued at $38,000 after buying an additional 15,151 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Cardiol Therapeutics by 66.2% during the 1st quarter. Royal Bank of Canada now owns 35,214 shares of the company’s stock valued at $54,000 after buying an additional 14,020 shares during the last quarter. Advisor Group Holdings Inc. raised its stake in shares of Cardiol Therapeutics by 2,240.7% during the 1st quarter. Advisor Group Holdings Inc. now owns 113,058 shares of the company’s stock valued at $173,000 after buying an additional 108,228 shares during the last quarter. Finally, Vident Investment Advisory LLC raised its stake in shares of Cardiol Therapeutics by 139.6% during the 1st quarter. Vident Investment Advisory LLC now owns 126,157 shares of the company’s stock valued at $195,000 after buying an additional 73,512 shares during the last quarter. Institutional investors and hedge funds own 16.64% of the company’s stock.
About Cardiol Therapeutics (Get Rating)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis.
- Get a free copy of the StockNews.com research report on Cardiol Therapeutics (CRDL)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.